Gene hunt in leukemia: what IDH mutations mean for patients
NCT ID NCT07004816
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to find how often IDH1 and IDH2 gene mutations occur in adults with acute myeloid leukemia (AML) in China, and whether those mutations affect a patient's chance of relapse or survival. Researchers planned to analyze stored leukemia samples from over 1,000 patients. The study was terminated early, so results may be limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tailored chemo cocktail outsmart a common leukemia?
- Can new drug cocktails beat back Hard-to-Treat leukemia?
- Can a pill and injection combo beat AML without harsh chemo?
- Can pressurized oxygen boost cord blood transplants?
- Personalized leukemia vaccine aims to outsmart relapse
- Supercharged donor cells aim to stop leukemia return after transplant